153 related articles for article (PubMed ID: 29292032)
1. ACE inhibition to slow progression of myocardial fibrosis in muscular dystrophies.
Russo V; Papa AA; Williams EA; Rago A; Palladino A; Politano L; Nigro G
Trends Cardiovasc Med; 2018 Jul; 28(5):330-337. PubMed ID: 29292032
[TBL] [Abstract][Full Text] [Related]
2. Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial.
Silva MC; Magalhães TA; Meira ZM; Rassi CH; Andrade AC; Gutierrez PS; Azevedo CF; Gurgel-Giannetti J; Vainzof M; Zatz M; Kalil-Filho R; Rochitte CE
JAMA Cardiol; 2017 Feb; 2(2):190-199. PubMed ID: 27926769
[TBL] [Abstract][Full Text] [Related]
3. Autonomic, locomotor and cardiac abnormalities in a mouse model of muscular dystrophy: targeting the renin-angiotensin system.
Sabharwal R; Chapleau MW
Exp Physiol; 2014 Apr; 99(4):627-31. PubMed ID: 24334334
[TBL] [Abstract][Full Text] [Related]
4. Progressive muscular dystrophy of heart: diagnosis easily missed by clinicians.
Gupta S; Duhan A; Marwah N; Hasija S; Sen R
Asian Cardiovasc Thorac Ann; 2014 Jan; 22(1):80-2. PubMed ID: 24585649
[TBL] [Abstract][Full Text] [Related]
5. [Cardiomyopathy in hereditary muscular dystrophies].
Hasselberg NE; Berge KE; Rasmussen M; Früh A; Ørstavik K; Haugaa KH
Tidsskr Nor Laegeforen; 2018 Jan; 138(1):. PubMed ID: 29313627
[TBL] [Abstract][Full Text] [Related]
6. Improved Cardiac Outcomes by Early Treatment with Angiotensin-Converting Enzyme Inhibitors in Becker Muscular Dystrophy.
Stalens C; Motté L; Béhin A; Ben Yaou R; Leturcq F; Bassez G; Laforêt P; Fontaine B; Ederhy S; Masingue M; Saadi M; Louis SL; Berber N; Stojkovic T; Duboc D; Wahbi K
J Neuromuscul Dis; 2021; 8(4):495-502. PubMed ID: 33814458
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2).
Morales MG; Cabrera D; Céspedes C; Vio CP; Vazquez Y; Brandan E; Cabello-Verrugio C
Cell Tissue Res; 2013 Jul; 353(1):173-87. PubMed ID: 23673415
[TBL] [Abstract][Full Text] [Related]
8. Are there real benefits to implanting cardiac devices in patients with end-stage dilated dystrophinopathic cardiomyopathy? Review of literature and personal results.
Palladino A; Papa AA; Morra S; Russo V; Ergoli M; Rago A; Orsini C; Nigro G; Politano L
Acta Myol; 2019 Mar; 38(1):1-7. PubMed ID: 31309174
[TBL] [Abstract][Full Text] [Related]
9. Cardiac management in neuromuscular diseases.
Allen HD; Thrush PT; Hoffman TM; Flanigan KM; Mendell JR
Phys Med Rehabil Clin N Am; 2012 Nov; 23(4):855-68. PubMed ID: 23137741
[TBL] [Abstract][Full Text] [Related]
10. Dystrophin-Deficient Cardiomyopathy.
Kamdar F; Garry DJ
J Am Coll Cardiol; 2016 May; 67(21):2533-46. PubMed ID: 27230049
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies.
Mavrogeni SI; Markousis-Mavrogenis G; Papavasiliou A; Papadopoulos G; Kolovou G
Methods Mol Biol; 2018; 1687():31-42. PubMed ID: 29067654
[TBL] [Abstract][Full Text] [Related]
12. Titin in muscular dystrophy and cardiomyopathy: Urinary titin as a novel marker.
Misaka T; Yoshihisa A; Takeishi Y
Clin Chim Acta; 2019 Aug; 495():123-128. PubMed ID: 30959043
[TBL] [Abstract][Full Text] [Related]
13. Prenatal diagnosis of congenital myopathies and muscular dystrophies.
Massalska D; Zimowski JG; Bijok J; Kucińska-Chahwan A; Łusakowska A; Jakiel G; Roszkowski T
Clin Genet; 2016 Sep; 90(3):199-210. PubMed ID: 27197572
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging therapies in Becker muscular dystrophy (BMD).
Angelini C; Marozzo R; Pegoraro V
Acta Myol; 2019 Sep; 38(3):172-179. PubMed ID: 31788661
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-dependent autonomic dysregulation precedes dilated cardiomyopathy in a mouse model of muscular dystrophy.
Sabharwal R; Weiss RM; Zimmerman K; Domenig O; Cicha MZ; Chapleau MW
Exp Physiol; 2015 Jul; 100(7):776-95. PubMed ID: 25921929
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological therapies for muscular dystrophies.
Abdel-Hamid H; Clemens PR
Curr Opin Neurol; 2012 Oct; 25(5):604-8. PubMed ID: 22941265
[TBL] [Abstract][Full Text] [Related]
17. Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy.
Tandon A; Villa CR; Hor KN; Jefferies JL; Gao Z; Towbin JA; Wong BL; Mazur W; Fleck RJ; Sticka JJ; Benson DW; Taylor MD
J Am Heart Assoc; 2015 Mar; 4(4):. PubMed ID: 25814625
[TBL] [Abstract][Full Text] [Related]
18. Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice.
Wada E; Tanihata J; Iwamura A; Takeda S; Hayashi YK; Matsuda R
Skelet Muscle; 2017 Oct; 7(1):23. PubMed ID: 29078808
[TBL] [Abstract][Full Text] [Related]
19. The Added Value of Cardiac Magnetic Resonance in Muscular Dystrophies.
Lamacie MM; Warman-Chardon J; Crean AM; Florian A; Wahbi K
J Neuromuscul Dis; 2019; 6(4):389-399. PubMed ID: 31561382
[TBL] [Abstract][Full Text] [Related]
20. Myocardial fibrosis imaging based on T1-mapping and extracellular volume fraction (ECV) measurement in muscular dystrophy patients: diagnostic value compared with conventional late gadolinium enhancement (LGE) imaging.
Florian A; Ludwig A; Rösch S; Yildiz H; Sechtem U; Yilmaz A
Eur Heart J Cardiovasc Imaging; 2014 Sep; 15(9):1004-12. PubMed ID: 24686257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
